Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of autoantibodies that can form immune complexes and deposit in tissues, causing inflammation and organ damage. There is evidence that interferons and some interleukins can have an active role in the pathogenesis of SLE and can contribute significantly to the immune imbalance in the disease, whereas the role of some cytokines (such as TNF) is still debated. This review discusses the activity of several cytokines in SLE, their effects on the immune cells in relation to the disease pathogenesis, and the promise and limitations of cytokine- based therapies in clinical trials for lupus patients.
Current Molecular Medicine
Title: Cytokines in Systemic Lupus Erythematosus
Volume: 9 Issue: 3
Author(s): Elaine V. Lourenco and Antonio La Cava
Affiliation:
Abstract: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of autoantibodies that can form immune complexes and deposit in tissues, causing inflammation and organ damage. There is evidence that interferons and some interleukins can have an active role in the pathogenesis of SLE and can contribute significantly to the immune imbalance in the disease, whereas the role of some cytokines (such as TNF) is still debated. This review discusses the activity of several cytokines in SLE, their effects on the immune cells in relation to the disease pathogenesis, and the promise and limitations of cytokine- based therapies in clinical trials for lupus patients.
Export Options
About this article
Cite this article as:
Lourenco V. Elaine and Cava La Antonio, Cytokines in Systemic Lupus Erythematosus, Current Molecular Medicine 2009; 9 (3) . https://dx.doi.org/10.2174/156652409787847263
DOI https://dx.doi.org/10.2174/156652409787847263 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Effects of Antioxidant Polyphenols on TNF-Alpha-Related Diseases
Current Topics in Medicinal Chemistry Selenium and Autoimmune Diseases: A Review Article
Current Rheumatology Reviews Naturally Arising CD25+CD4+ Regulatory T Cells in Maintaining Immunologic Self-Tolerance and Preventing Autoimmune Disease
Current Molecular Medicine The Prevalence of the Classical and Non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets Serological Electrodetection of Rheumatoid Arthritis Using Mimetic Peptide
Protein & Peptide Letters Pharmacokinetic and Toxicological Characteristics of Tripterigium Glycosides and Their Derivatives
Current Drug Metabolism The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Current Drug Targets Altered Peptide Ligand Antagonism: From Immune Evasion to Immunotherapy
Drug Design Reviews - Online (Discontinued) Dietary N-3 Fatty Acids and Calorie Restriction in Autoimmune Disease:Influence in Different Immune Compartments
Current Organic Chemistry Therapeutic Potential of Natural Products from Terrestrial Plants as TNF-α Antagonist
Current Topics in Medicinal Chemistry Inhibition of Type 1 Diabetes Development by Vitamin D Receptor Agonists
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Synthetic Peptides Derived from Ribosomal Proteins of Leishmania spp. in Mucocutaneous Leishmaniasis: Diagnostic Usefulness
Protein & Peptide Letters PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Endocrine, Metabolic & Immune Disorders - Drug Targets Ablation of T-Helper 1 Cell Derived Cytokines and of Monocyte-Derived Tumor Necrosis Factor-α in Hereditary Hemorrhagic Telangiectasia: Immunological Consequences and Clinical Considerations
Current Pharmaceutical Design Mouse Models of Autoimmune Diseases: Immune Thrombocytopenia
Current Pharmaceutical Design Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Regulation of B Cell Activation by PECAM-1: Implications for the Development of Autoimmune Disorders
Current Pharmaceutical Design Thrombotic Management of Antiphospholipid Syndrome: Towards Novel Targeted Therapies
Current Vascular Pharmacology